Pall Corp. agreed to acquire ATMI Inc life science business for $185 million to strengthen the company's market standing. The maker filtration and purifications products expects the purchase of ATMI LifeSciences -- which makes single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries-- to add $20 million to $30 million to Pall's revenue.
ATMI is +4% and PLL is flat in early trading today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”